Skip to content
ClinCalc Pro
Menu
5-HT3 Receptor Antagonist (Antiemetic)

Ondansetron (Perioperative)

Brand names: Zofran

Perioperative ondansetron is a 5-HT3 receptor antagonist used to prevent and treat post-operative nausea and vomiting, commonly given towards the end of surgery.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Ondansetron selectively blocks 5-HT3 (serotonin) receptors centrally at the chemoreceptor trigger zone and peripherally on vagal afferents, interrupting the emetic reflex.

Prescribing in practice

  • Ondansetron prolongs the QT interval — avoid or use with caution alongside other QT-prolonging drugs (including some anaesthetic agents), in congenital long QT syndrome, and correct hypokalaemia and hypomagnesaemia.
  • It is most effective as part of a multimodal antiemetic strategy combining agents from different classes for high-risk patients rather than as a sole agent.
  • Common effects include headache and constipation, and rare serotonin syndrome can occur with other serotonergic drugs.

Monitoring

Consider ECG and electrolyte checks in patients with cardiac risk factors or on other QT-prolonging therapy, and monitor for ongoing nausea requiring an additional class of antiemetic.

Counselling the patient

  • This medicine helps stop sickness after your operation.
  • Tell staff if you still feel sick, as a different anti-sickness drug can be added.
  • Headache is a common, harmless side effect.

Evidence & guidelines

5-HT3 antagonists are guideline-recommended first-line agents for prevention of post-operative nausea and vomiting.

Reference: MHRA Drug Safety Update 2013; Apfel PONV Risk Score; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.